Amoy Diagnostics Co., Ltd.

Equities

300685

CNE1000034D3

Medical Equipment, Supplies & Distribution

End-of-day quote Shenzhen S.E. 23:00:00 12/05/2024 BST 5-day change 1st Jan Change
20.65 CNY -2.91% Intraday chart for Amoy Diagnostics Co., Ltd. -6.81% -6.05%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Amoy Diagnostics Co., Ltd. commences an Equity Buyback Plan for CNY 200 million worth of its shares, under the authorization approved on February 26, 2024. CI
Amoy Diagnostics Co., Ltd.(SZSE:300685) dropped from Shenzhen Stock Exchange Component A Share Index CI
Amoy Diagnostics Co., Ltd.(SZSE:300685) dropped from Shenzhen Stock Exchange Component Index CI
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Amoy Diagnostics to Collaborate with AstraZeneca Unit for Ovarian Cancer Companion Diagnostic in China MT
Amoy Diagnostics Co., Ltd. Announces 2022 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date of 23 May 2023 CI
Amoy Diagnostics Co., Ltd. Approves Final Dividend for 2022 CI
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Amoy Diagnostics Co., Ltd. Proposes Final Cash Dividend for the Year 2022 CI
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd. and Precision Medicine Asia Co., Ltd. Announces the Japanese Ministry of Health, Labour and Welfare Approval in Japan as a Companion Diagnostic for Ret Fusion-Positive NSCLC CI
Tranche Update on Amoy Diagnostics Co., Ltd.'s Equity Buyback Plan announced on February 14, 2022. CI
Amoy Diagnostics Co., Ltd.'s Equity Buyback announced on February 13, 2023 has expired with 3,943,726 shares, representing 1% for CNY 112.01 million. CI
Tranche Update on Amoy Diagnostics Co., Ltd.'s Equity Buyback Plan announced on February 14, 2022. CI
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Tranche Update on Amoy Diagnostics Co., Ltd.'s Equity Buyback Plan announced on February 14, 2022. CI
Alercell® to Distribute Amoydx® Ros1 Gene Fusion Detection Kit CI
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Tranche Update on Amoy Diagnostics Co., Ltd.'s Equity Buyback Plan announced on February 14, 2022. CI
Amoy Diagnostics Co., Ltd. Announces Dividend, Payable on May 31, 2022 CI
Amoy Diagnostics Co., Ltd. Approves Dividend for 2021 CI
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Chart Amoy Diagnostics Co., Ltd.
More charts
Amoy Diagnostics Co Ltd is a pharmaceutical company engaged in research, development, production and sales of molecular diagnostic products. The Company provides testing reagents and testing services for tumor diagnosis. The Company’s testing reagent products include ADx-ARMS product line for tumor tissue specimen detection, Super-ARMS product line for liquid biopsy, the NGS product line and the FISH product line. The products are used for the detection of non-small cell lung cancer, colorectal cancer, thyroid cancer, melanoma and other malignant tumors. The Company also provides data software to capture and analyze gene sequencing data. The Company provides testing services through its own medical testing institutions, including lung cancer testing, colorectal cancer testing and breast cancer testing.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
20.65 CNY
Average target price
28.6 CNY
Spread / Average Target
+38.48%
Consensus
  1. Stock Market
  2. Equities
  3. 300685 Stock
  4. News Amoy Diagnostics Co., Ltd.
  5. Amoy Diagnostics to Collaborate with AstraZeneca Unit for Ovarian Cancer Companion Diagnostic in China